Societe Generale Asset Management

Societe Generale Asset Management, a French multinational banking and financial services firm, offers investment solutions for its clients.

Business Model:

Revenue: $0

Employees: 0-0

Rankings

Industries / Tags:

Detailed Societe Generale Asset Management Information

Geographic Data

Societe Generale Asset Management headquarters map

Address:

City:

State:

Zip:

Country:

Financial Info

Stage:

Raised Last:

$0

Raised Total:

$0

Metrics

0Website Global Rank

0Website Monthly Traffic

Twitter Followers

Description

SGAM AI is a leading institutional player in Alternative Investment Management. SGAM AI successfully mixes the cultures of asset management and capital markets. They are client driven and institutional, like an asset manager. Their approach of each market is entrepreneurial and financial, like an investment bank. They offer the widest coverage of Alternative Investment classes. Their size and profitability allow long term investments and credibility. They have the ability to offer solutions, not only products. SG Group&s;s strengths are brought to the Alternative Investment&s;s industry. They benefit from SG Group&s;s long term commitment in Alternative Investments. They use the processes ans resources of SGAM Group (rated M2 by Fitch).

Contact Phone:

Contact Email:

Announced Date Company Transaction Money Raised
12/2005 Genomic Vision Series A 2.4M
6/2000 MakeMusic, Inc. Series C 0
1/2001 Netasq Series A 1.6M
11/2009 Force-A Series B 2.1M
7/2007 Diatos Series D 12.8M
7/2001 Ornis Venture Round 4.4M
2/2003 Cariocas Series B 5.3M
11/2007 Arterial Remodeling Technologies Venture Round 8M
6/2006 Chronicle Solutions Series A 5.5M
4/2008 Jobpartners Series C 0
7/2008 Genomic Vision Series B 6.3M
1/2006 Ariane Systems Venture Round 3.1M
5/2006 NEMOPTIC Series D 0
8/2006 Augure Series C 5.8M
8/2000 MEDoctor Seed Round 0
12/2003 DiBcom Venture Round 0
4/2005 Biosystems International Seed Round 3.9M
5/2008 Genkyotex Series A 4M
3/2003 CellZome Series C 32M
2/2006 Cytomics Pharmaceuticals Series B 11.9M
10/2006 Infront Analytics Series C 2.8M
11/2002 BioForce Nanosciences Venture Round 2M
11/2005 IntegraGen Series B 9.4M
9/2007 GQ Life Sciences Series B 0
1/2004 Cyclacel Pharmaceuticals Series D 38.7M
10/1999 Drug Abuse Sciences Venture Round 22.4M
10/2007 Ekinops Series B 20M
9/2008 Augure Series D 11.3M
2/2005 Sequans Communications Series B 9.3M
9/2005 Univa Venture Round 15M
1/2002 Netasq Series B 3.6M
2/2005 Augure Series B 1.6M
1/2008 Adocia Venture Round 17.4M
1/2004 DiBcom Series C 0
7/2004 Netasq Series C 4.1M
3/2002 DiBcom Series B 2.6M
12/2003 Ornis Venture Round -
6/2005 DiBcom Series D 0
1/2001 DiBcom Series A 2.3M
10/2006 Open-Plug Series B 15M
1/2006 DxO Labs Series A 12.8M
7/2007 DiBcom Series E 0
10/2006 Sequans Communications Series C 24M
3/2007 Force-A Series A 3M
3/2001 Drug Abuse Sciences Series A 46.5M
12/2002 Catalyst Bioscience Venture Round 46M
11/2009 Force-A Series B 0
9/2008 Augure Series D 0
7/2008 Genomic Vision Series B 0
5/2008 Genkyotex Series A 0
4/2008 Jobpartners Series C 0
1/2008 Adocia Venture Round 0
11/2007 Arterial Remodeling Technologies Venture Round 0
10/2007 Ekinops Series B 0
9/2007 GQ Life Sciences Series B 0
7/2007 DiBcom Series E 0

Startup Industries

Startup Locations

Portfolio Current Status

Portfolio Employee Count

Name Price
Name Size Announced Date

You know, we could be doing all this for you..

CoBee's Logo

Be ahead of your competition

  • Realtime intelligence
  • Automated contact tracking
  • Unmatched insights
  • Eliminate manual research